Valneva

New Capabilities

Developer of the vaccine candidate; bearing 40% of development costs

The last Lyme disease vaccine was pulled from the market in 2002 after unfounded safety fears destroyed demand. Twenty-four years later, Pfizer and French biotech Valneva announced that their replacement candidate showed 73% efficacy in a Phase 3 trial of over 9,000 participants, and said they will seek Food and Drug Administration (FDA) approval this year with a possible launch in late 2027.

Updated 3 hours ago